Related Experiment Videos
[Multicenter study of a slow-release theophylline: armophylline]
Le Poumon Et Le Coeur
|January 1, 1983
Summary
This study shows Armophylline, a new slow-release theophylline, effectively treats asthma. Patients experienced reduced symptoms and improved lung function with generally mild side effects.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Asthma management requires effective bronchodilators.
- Theophylline is a widely used bronchodilator.
- Slow-release formulations aim to improve patient compliance and reduce side effects.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Armophylline, a novel slow-release theophylline formulation.
- To assess the impact of Armophylline on asthma symptoms and pulmonary function.
Main Methods:
- A co-operative study involving 10 centers and 95 asthmatic patients.
- Patients were treated with Armophylline for 1 to 3 months.
- Dosage ranged from 11 to 15 mg/kg/day, with blood theophylline levels monitored.
Main Results:
- Eighty percent of patients achieved adequate blood theophylline levels (7-20 mcg/ml).
- Significant reductions in dyspnea and asthma attacks were observed.
- Significant improvements in FEV1 and FEV1/VC ratio were noted.
Conclusions:
- Armophylline is an effective slow-release theophylline for asthma treatment.
- The drug demonstrates a favorable safety profile with generally mild side effects.
- Armophylline improves respiratory function and reduces asthma exacerbations.